Clinical Trial Update: Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial update of alemtuzumab and ofatumumab in previously untreated symptomatic chronic lymphocytic leukemia; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Northwestern University | Conditions: Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-01-22